RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Extended lab space for product development, customer demos, and training
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Subscribe To Our Newsletter & Stay Updated